Application of N, N-dimethylglycine in preparation of medicine for treating androgenetic alopecia
By using N,N-dimethylglycine (DMG) as an external application product, the existing androgenic hair loss treatment methods have solved the problem of adverse reactions and limited efficacy, and the effect of improving hair growth status and quality and increasing hair follicles is achieved.
Patent Information
- Application Number
- CN202411835935.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-13
- Publication Date
- 2025-03-18
AI Technical Summary
The existing androgenic hair loss treatment methods have problems with adverse reactions and limited efficacy, and there is a lack of effective adjuvant treatment plans.
N,N-dimethylglycine (DMG) is used as a new drug for the treatment of androgenic hair loss. The concentration of DMG is 1%-3% and contains pharmaceutically acceptable carriers or excipients.
DMG significantly improves the hair growth status and quality of androgenic hair loss mice, increases the number of hair follicles, promotes hair regeneration, and has no adverse reactions to the body.
Smart Images
Figure CN119632968A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology and relates to the application of N,N-dimethylglycine in the preparation of a drug for treating androgenic alopecia. Background Art
[0002] Androgenetic alopecia (AGA), also known as seborrheic alopecia, is the most common type of hair loss clinically.
[0003] The clinical manifestations of AGA are smooth, oily, and flaky skin in the hair loss area, and the hair in the frontal and temporal areas and on the top of the head gradually becomes sparse or even completely falls out. The characteristics of male pattern baldness patients are mostly manifested by the gradual and significant thinning of the hair in the frontal and temporal areas and on the top of the head, a decrease in density, and a receding hairline. At the same time, the hair also begins to thin at the top of the head, eventually leading to baldness. Female patients mainly show progressive reduction and thinning of the hair on the top of the head, and some show diffuse thinning of the hair, which is called female pattern baldness. Currently, there are not many proven effective treatments for AGA, and all of them are accompanied by certain adverse reactions. For example, minoxidil has been approved for use in male and female androgenic alopecia since 1984, but it can cause allergic dermatitis, pain and hirsutism. Case reports show that topical use of minoxidil can cause fetal malformations, so it is not recommended for pregnant women and lactating women. Oral finasteride or dunasteride has side effects such as headache, anxiety, memory loss, erectile dysfunction and insulin resistance. Common side effects of laser treatment include headache, erythema, edema and hair shaft damage. Microneedle therapy combined with minoxidil has better effects, and the main side effects are local pain and bleeding. Hair transplantation is currently one of the most effective ways to treat hair loss, but hair transplantation has the defects of high surgical costs, long recovery time, postoperative pain and infection, and hair transplantation is the displacement of hair, which does not increase the number of hair follicles. Its related clinical research is still in the early stages of exploration and still faces many problems and challenges. The only approved drugs are minoxidil and finasteride. Therefore, it is necessary to find new or auxiliary drugs for the treatment of AGA. N,N-dimethylglycine (DMG) is a naturally occurring amino acid that is metabolized normally in the body. According to toxicity studies, it does not produce genotoxic, carcinogenic or teratogenic effects. Therefore, if N,N-dimethylglycine can be used to treat AGA, it will be good news for AGA patients. Summary of the invention
[0004] In view of the above situation and on the basis of the above research, the present invention proposes a new application of DMG in the treatment of androgenic alopecia, which has the effect of improving androgenic alopecia.
[0005] In order to achieve the above object, the present invention adopts the following technical means:
[0006] The inventors of the present invention have found through research that the compound DMG can improve the hair growth condition and quality of AGA mice, thereby improving androgenic alopecia. Therefore, the compound has broad application prospects in the treatment of AGA.
[0007] In the above application, the linear molecular formula of N,N-dimethylglycine (DMG) is (CH3)2NCH2COOH.
[0008] In the above application, the concentration of DMG-Na in the medicine is 1%-3%.
[0009] In the above application, the medicine further comprises a pharmaceutically acceptable carrier or excipient.
[0010] In the above application, the medicine is an external application product, and the external application product includes one of ointment, cream, gel, spray, emulsion, patch, powder or film.
[0011] Compared with the prior art, the present invention has the following beneficial effects:
[0012] The present invention provides for the first time a new use of the compound DMG in treating AGA. The compound improves the hair growth condition and quality of AGA mice and has no adverse reactions to the body. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 DMG promotes hair growth in AGA mice, where (A) is a photo of the mouse hair growth experiment; (B) a mouse back skin color score scale; (C) the results of the mouse back skin color score change; quantification of the mouse skin color score shown in (A) based on the mouse skin color score, where Day 7 and Day 10: Con group vs. SAG group, AGA group vs. 1% DMG group had significant differences, P<0.05; (D) mouse weight changes.
[0014] Figure 2 The effect of DMG on the quality of newly grown hair in AGA mice. (A) is the scanning electron microscope (SEM) image of newly grown hair; (B) is the statistics of hair diameter; (C) is the statistics of hair scale length.
[0015] Figure 3 Effects of DMG on hair follicles in the skin of AGA mice; (A) Con group; (B) AGA group; (C) 3% DMG group; (D) 1% DMG group; (E) Number of hair follicles per unit area in HE-stained sections of each group, where Bulb: hair bulb; ORS: outer root sheath; HS: hair shaft. DETAILED DESCRIPTION
[0016] The present invention will be further described below in conjunction with examples. It should be noted that the following examples are only for illustration, and are not intended to limit the present invention. Various changes made by those skilled in the art based on the teachings of the present invention should all be within the scope of protection required by the claims of the present application.
[0017] Example 1 Effect of compound DMG on promoting hair growth in AGA mice
[0018] 1. Mouse husbandry and experimental methods
[0019] Twenty-four 6-week-old male C57BL / 6 mice (weight 20g-22g) were randomly divided into negative control group, AGA group, low-dose treatment group, and high-dose treatment group, with 6 mice in each group. All mice were subjected to subsequent experiments after 1 week of adaptive feeding. The hair on the back of the mice was removed using a razor and depilatory wax paper, and a 2cm×3cm skin experimental area was left. The negative control group was smeared with normal saline (Con group), the AGA group was injected with testosterone propionate injection (AGA group), the low-dose treatment group was smeared with 1% DMG (1% DMG group), and the high-dose treatment group was smeared with 3% DMG (3% DMG group). During the experiment, the mice were guaranteed to have free access to food and water, and the bedding was changed regularly to ensure the growth status of the mice. During the animal experiment, there was no significant difference in body weight among the groups. In addition, no other clinical symptoms occurred during the experiment. The modeling method was based on the previous method, that is, except for the Con group, each mouse was subcutaneously injected with testosterone propionate injection 5mg / kg / d on the back according to body weight until the end of the experiment.
[0020] 2. Scoring of Mouse Hair Regeneration
[0021] After removing the hair from the back of C57BL / 6 mice, the skin on the back of the mice turned pink, and the hair follicles were in the resting stage. In order to compare the effects of different treatments on hair regeneration in mice, photos were taken on the 0th, 7th, 10th and 14th days after hair removal. Figure 1 As shown in (A), the hair growth was evaluated. The hair on the back of the mouse was scored from 1 to 5 according to the mouse back skin color score scale. The hair growth of the mouse was scored by 4 people and the average was taken as the final score. Figure 1 As shown in (B) and (C).
[0022] Figure 1 The results in (D) showed that there was no significant difference in the body weight of mice in each group compared with the blank control group, indicating that DMG had no obvious side effects on mice. According to the scoring results, the hair growth rate of AGA mice was slower than that of the Con group, with a significant difference; 1% DMG and 3% DMG could accelerate the hair growth rate of AGA mice, and the hair growth rate of mice in the 1% DMG group on the 7th and 10th days was significantly different from that of AGA mice.
[0023] 3. Evaluation of the quality of new hair
[0024] Using SEM, we can directly observe the changes in hair diameter and hair scales, such as Figure 2 As shown in (A), the quality of the newly grown hair is evaluated. Thick newly grown hair with large scales indicates good hair quality. Figure 2 As shown in (B) and (C), the hair diameter and hair scale size of the AGA group mice were significantly smaller than those of the blank group mice; the hair diameter and hair scale size of the 1% DMG group and 3% DMG group mice were significantly larger than those of the AGA group mice, indicating that DMG can improve the quality of new hair.
[0025] 4. Assessment of hair follicle growth
[0026] At the end of the experiment, the mice were killed and the skin of the experimental area (28 days) was cut and placed in 4% paraformaldehyde tissue fixative for 24 hours. After dehydration with 30% sucrose solution, the skin was embedded, sliced, dehydrated, stained with hematoxylin-eosin, and sealed. The results were observed and recorded under an optical microscope. Figure 3 It can be seen that the hair follicle density of the control group mice ( Figure 3 A) was greater than that of the AGA group ( Figure 3 B), indicating that the model was successfully established. In the skin of mice in the Con group and DMG group, most hair follicles showed enlarged bulbs and melanin production, and grew deep into the dermis and subcutaneous layer, indicating that they had entered the growth phase. In the AGA group, the hair follicles were still located in the upper part of the dermis, and there was no significant enlargement of the bulbs and melanin production, indicating that they were in the resting phase, indicating that 1% DMG and 3% DMG can promote the transition of hair follicles from the resting phase to the growth phase, promote hair follicle regeneration, increase the number of hair follicles, and thus promote hair regeneration. Five unit surfaces were selected for each slice. The number of hair follicles in the HE staining images of each group was counted using the counting function of Image J ( Figure 3 (E), the results showed that both 1% DMG and 3% DMG could improve the growth of hair follicles in AGA mice.
Claims
1. Application of N,N-dimethylglycine DMG in the preparation of drugs for the treatment of androgenic alopecia.
2. The use according to claim 1, characterized in that: The concentration of DMG in the drug is 1%-3%.
3. The use according to claim 2, characterized in that: The method of promoting hair growth in AGA mice is to promote hair follicle regeneration, increase the number of hair follicles, and thus promote hair regeneration.
4. The use according to claim 1, characterized in that: The medicament further comprises a pharmaceutically acceptable carrier or excipient.
5. The use according to claim 1, characterized in that: The medicine is an external application product, which includes one or more of ointments, creams, gels, sprays, emulsions, patches, powders or films.